查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2095034

次要大麻素市場－2026-2032年全球市場預測

Minor Cannabinoids Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，次要大麻素市場將成長至 358.6 億美元，複合年成長率為 8.55%。

主要市場統計數據
基準年 2025 201.9億美元
預計年份：2026年 216.9億美元
預測年份 2032 358.6億美元
複合年成長率 (%) 8.55%

包括大麻酚、大麻酚、大麻色烯、四氫大麻酚酸、大麻二酚酸以及新興的酸性化合物和纈氨酸化合物在內的次要大麻素，正從植物化學領域的細分方向轉向健康、藥物研發、化妝品、功能性成分和受監管大麻產品開發等領域的戰略重點。與市售大麻產品中最常見的主要大麻素不同，次要大麻素在自然界中的濃度通常很低，需要先進的育種、生物合成、精確萃取、分離和分析檢驗才能大規模應用。由於這些化合物獨特的受體相互作用、潛在的協同效應和差異化的製劑特性，人們對它們的科學興趣日益濃厚，但許多療效聲明仍處於臨床研究階段，需要嚴格的監管審查。品質保證、污染物檢測、藥物動力學研究、消費者對特定功效的需求以及司法管轄區的合規要求，正日益影響著該行業的發展。相關人員在評估次要大麻素的商業機會時，成功的關鍵在於基於證據的產品開發、透明的標籤、供應鏈可追溯性，以及對健康功效聲明採取嚴格方法，使其符合適用的大麻、食品、補充劑、化妝品和藥品法規。

一項變革性的改變，將徹底改變次要大麻素的格局。

次要大麻素領域正經歷一場變革性的轉變，從頻譜大麻萃取物轉向更精準、更標準化的配方，旨在實現特定功效。植物遺傳學的進步使得培育出大麻素（如CBG和THCV）濃度較高的品種成為可能，同時，基於發酵和生物合成的生產方法也正在被探索，以應對植物含量低和批次間差異大等挑戰。同時，層析法、質譜法和參考物質等檢測技術的改進，正在加強大麻素的鑑定和純度檢驗，這對於臨床研究、產品安全以及獲得監管機構的信任至關重要。消費者群體也從泛泛的CBD健康理念轉向以改善睡眠、放鬆身心、提升專注力、促進恢復和改善皮膚健康為重點的功效導向型產品，儘管不同司法管轄區對功效證明的要求差異很大。對大麻衍生精神活性化合物、合成途徑、殘留溶劑、標籤準確性以及年齡限制等方面的監管日益嚴格。這些變化正促使該行業從以潮流主導的商業化模式轉向以藥品級文件、檢驗的生產控制以及基於證據的功效聲明為導向的模式。

人工智慧對次要大麻素的累積影響

人工智慧正透過加速化合物發現、最佳化種植變數、提高萃取效率和支持監管洞察，對次要大麻素價值鏈產生日益顯著的影響。在田間應用方面，機器學習模型正被用於分析大麻素與受體的相互作用、篩檢分子類似物，並識別有潛力的候選藥物以進行進一步的實驗室和臨床評估。在農業領域，人工智慧驅動的環境監測透過將頻譜、營養成分、濕度和收穫時間與大麻素表達關聯起來，幫助支持可控種植並降低特種生質能的變異性。在製造業，預測分析可以改善提取、純化和穩定性測試的製程控制，而電腦視覺和光譜系統可以增強品質控制。人工智慧也被應用於不利事件監測、文獻監測、專利映射以及在分散的大麻法規中進行合規性追蹤。然而，人工智慧的累積效應取決於資料品質、模型檢驗、隱私管理和人工監督。由於大麻素科學仍然是一個不斷發展的實證領域，人工智慧應該用於補充實驗設計和決策，而不是取代毒理學、藥理學、臨床檢驗或監管審查。

對次要大麻素生態系統的關鍵區域性見解

亞太地區正逐漸成為大麻素研究和合法醫用大麻開發的重要科學區域。澳洲、日本、韓國、印度、中國和泰國在大麻衍生成分、藥物研發路徑、大麻種植和工業應用方面各有不同。澳洲已建立起合法醫用大麻的取得途徑和研究活動，而日本和韓國則維持著嚴格的監管，並對大麻素的使用許可進行細緻的界定，儘管人們對非精神活性成分的興趣日益濃厚。在中國，儘管工業大麻活動歷史悠久，尤其是在纖維和種子用途方面，但在某些省份，大麻素的使用仍然受到嚴格限制。北美仍然是次要大麻素商業開發最先進的地區，這得益於加拿大的聯邦大麻法規結構以及美國州級大麻監管市場和聯邦級大麻監管標準的複雜分化。該地區的複雜性促進了CBG、CBN、CBC和THCV產品的創新，同時也引發了執法部門對致幻性大麻衍生物和標籤不一致的擔憂。拉丁美洲正透過醫用大麻立法、大麻政策辯論以及藥品進口路線而日益重要，其中巴西、墨西哥、哥倫比亞、阿根廷和智利在患者獲取途徑、種植許可和監管成熟度方面存在差異。歐洲的特點是對新型食品、藥品、麻醉品和化妝品實施嚴格的監管，要求對大麻素成分，特別是分離或濃縮的次要大麻素，進行高度合規的監管。中東地區仍保持謹慎，一些司法管轄區在嚴格控制下允許有限地獲取醫用或藥用大麻素，但更廣泛的大麻商業化仍然受到嚴格限制。在非洲，一些已製定醫用大麻和工業大麻框架的國家具有長期的種植和出口潛力，但基礎設施、認證、投資和國際合規要求仍然是進入次要大麻素供應鏈的關鍵因素。

主要團體對次要大麻素的監管和推廣的看法

在東協地區，各國對次要大麻素的政策方針仍高度多樣化，從泰國的實驗性大麻政策及其後續收緊的監管，到新加坡、馬來西亞、印尼、越南和菲律賓更為嚴格的監管制度，不一而足。在這些國家，毒品法律對商業大麻素活動有顯著的限制。這為醫療、研究和工業大麻相關用途創造了有限的機遇，但也要求在司法層面進行嚴格審查。海灣合作理事會（GCC）成員國擁有世界上最嚴格的毒品法規環境；雖然在特定情況下可以透過受控的醫療管道獲得醫用大麻素，但商業次要大麻素產品面臨著巨大的法律障礙。歐盟擁有涵蓋毒品管制、食品安全評估、新食品授權、化妝品法規和國家級醫用大麻體系的複雜框架，因此合規文件、毒理學數據和成分可追溯性對於市場准入至關重要。金磚國家整體情況則更為複雜。巴西和南非已建立醫用大麻和工業大麻相關活動的框架，而中國和印度在工業或傳統植物用途方面對大麻素有嚴格的監管，俄羅斯則維持限制性的大麻法律。七國集團（G7）對品質標準、藥物安全監測實務、分析檢測要求和消費者安全標準的製定具有特別重要的影響力，加拿大、美國、德國、法國、義大利、日本和英國對大麻和工業大麻的監管各不相同。北約成員國的監管情況也存在差異。北美和歐洲成員國在醫用大麻、工業大麻衍生的大麻素的取得、產品標籤和國防相關法規等方面持有不同觀點，但它們普遍強調受控供應鏈、檢驗的檢測以及政策與公共衛生和安全目標保持一致的重要性。

主要國家影響次要大麻素策略的趨勢

美國是次要大麻素創新最活躍的地區之一，這得益於各州的大麻項目、以工業大麻為基礎的產品開發以及消費者對特定大麻素形式的興趣；然而，聯邦層面的不確定性和各州層面的法規造成了合規方面的複雜性。加拿大受益於支持受監管產品開發和分析監督的國家大麻框架，使其成為標準化大麻素形式的重要市場。在墨西哥，圍繞大麻的法律和政策辯論愈演愈烈，但關於廣泛的商業性大麻素活動的實際清晰度仍然有限​​。巴西是一個值得關注的國家，該國可以透過衛生部門的核准途徑獲得醫用大麻，患者的需求主要受處方箋和進口機制的影響。在英國，鑑於醫用大麻的嚴格處方制度以及對CBD和受監管大麻素的特定規定，次要大麻素的商業化取決於嚴格的合規性。德國因其醫用大麻體系和在成人使用改革方面取得的進展而具有影響力。同時，法國保持謹慎的態度，這主要受臨床試驗、工業大麻法規和對消費品的嚴格監管的影響。俄羅斯對大麻和類大麻素的商業化仍然持限制態度。義大利和西班牙正在積極討論工業大麻和醫用大麻，但兩國都必須嚴格遵守國內關於四氫大麻酚（THC）閾值、產品功效標籤和麻醉品管制等方面的法規。由於國內法規嚴格，中國更專注於工業大麻的生產能力和製造技術，而非開放的類大麻素消費市場。印度擁有與大麻相關的傳統背景，製藥業也對此很感興趣，但現代類大麻素的商業化必須符合麻醉品管制、國家法規和醫療法規。日本雖然對大麻有嚴格的監管，但在特定條件下，它傾向於選擇性批准並加強對非精神活性類大麻素成分的審查。澳洲擁有系統性的醫用大麻框架和完善的患者獲取管道，使其成為大麻素研究和受監管產品的重要市場。韓國允許在受控條件下有限地獲取醫用大麻，但對類大麻素的更廣泛商業化實施了嚴格的限制。

為行業領導者提供的實用建議

產業領導者應優先考慮基於證據的差異化，投資於檢驗的分析測試、穩定性數據、毒理學評估，並在適當情況下進行臨床和觀察性研究。產品開發團隊應避免做出未經證實的療效聲明，而應確保標籤、行銷和消費者教育符合各司法管轄區針對大麻、工業大麻、膳食補充劑、食品、化妝品和藥品的具體法規。供應鏈管理人員應加強從遺傳因素和生物合成原料到成品的可追溯性，包括記錄大麻素鑑定、殘留溶劑、農藥、重金屬、微生物污染物以及轉化產品的特定資訊。製造商應評估植物來源、濃縮生質能、半合成轉化或生物合成是否最符合其各自司法管轄區的法律體制和品質要求。監管回應團隊必須積極監測有關精神活性工業大麻衍生物、新型食品、醫用大麻取得、進出口法規以及管制物質認定等方面的快速變化的政策。企業領導者應專注於打造目標明確、透明的產品組合，清楚釐清大麻素含量、單次劑量、起效時間和安全性注意事項。與經認證的檢測實驗室、臨床研究人員、種植者和監管專家建立策略合作夥伴關係，有助於降低風險並提升信譽。最重要的是，領導者應建構「合規至上」的營運模式，以適應快速變化的政策，同時保障消費者安全和科學誠信。

調查方法

本執行摘要採用系統性的二手研究途徑編寫，重點檢驗的公共領域資訊來源、監管文件、科學文獻和行業相關政策資料。此調查方法強調對政府出版刊物、衛生部門指南、同行評審研究、國際藥品監管參考資料、標準化機構和公開的法律體制進行交叉檢驗。為聚焦監管、技術、科學和策略趨勢，本分析未涉及市場規模、市場佔有率和預測。在適用情況下，透過比較大麻、工業大麻、醫療用途、管制物質、食品、膳食補充劑、化妝品和藥品的相關法規，整合了區域、群體和國家層面的具體見解。科學解讀在一個獨立的框架內呈現，區分了臨床前試驗結果、早期研究、已批准的大麻素藥物醫療用途和檢驗的商業性聲明。技術見解，包括人工智慧 (AI) 應用，透過其與種植、萃取、分析、藥理學、產品開發和合規營運流程的相關性進行評估。該研究方法優先考慮準確性、可追溯性和對決策者在不斷變化的次要大麻素生態系統中行事的實際意義。

結論

由於其在獨特配方開發方面的潛力、日益成長的研究價值以及精準產品開發的新機遇，微量大麻素在整個大麻和工業大麻生態系統中正受到越來越多的關注。然而，永續成長之路更取決於證據、合規性、安全性和生產一致性，而非其新穎性。區域和國家監管差異仍然是最重要的戰略挑戰之一，尤其對於分離、濃縮、生物合成或化學轉化的大麻素更是如此。儘管人工智慧、高級分析、可控種植和改進的純化技術正在增強行業識別、標準化和檢驗微量大麻素成分的能力，但科學基礎和負責任的商業化仍然至關重要。那些能夠將嚴格的測試、透明的標籤、靈活的監管策略和值得信賴的研究夥伴關係關係相結合的機構，將更有利於建立人們對微量大麻素在醫療、保健、化妝品和特殊消費品應用領域的信心。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 次要大麻素市場：依產品類型分類

  • 大麻鉻
  • 大麻酚
  • 大麻酚
  • Delta-8-THC
  • THCV

第8章：次要大麻素市場：依形式分類

  • 飲料
    • 能量飲料
    • 含大麻素的水
    • 茶
  • 膠囊
  • 食用產品
    • 燒製產品
    • 巧克力
    • 軟糖
  • 油
  • 酊劑
  • 外用製劑

第9章：次要大麻素市場：依應用領域分類

  • 醫療和治療用途
    • 疼痛管理和發炎管理
    • 睡眠與晝夜節律紊亂
    • 焦慮、壓力和情緒障礙
    • 神經系統和神經保護用途
    • 代謝和食慾調節
  • 健康與生活方式應用
    • 每日放鬆和緩解壓力
    • 專注力、活力、生產力
    • 健身和運動恢復
    • 健康老化和長壽
  • 化妝品和個人護理應用
    • 護膚
    • 頭髮和頭皮護理
    • 口腔和牙齒護理
  • 獸醫應用
    • 伴侶動物
    • 用於比賽和勞動的動物

第10章：次要大麻素市場：依銷售管道分類

  • 線上管道
  • 離線頻道

第11章 次要大麻素市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第12章 次要大麻素市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 次要大麻素市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第15章：公司簡介

  • Amyris, Inc.
  • Aurora Cannabis Inc.
  • BayMedica
  • Biomedican Inc.
  • Bluebird Botanicals, LLC
  • Botanacor Laboratories, Inc.
  • Canopy Growth Corporation
  • Cronos Group, Inc.
  • CV Sciences, Inc.
  • Demetrix, Inc.
  • ExtraktLAB, Inc.
  • Folium Biosciences, Inc.
  • Ginkgo Bioworks, Inc.
  • Green Thumb Industries Inc
  • GW Pharmaceuticals Limited
  • Hyasynth Bio, Inc.
  • Isodiol International Inc.
  • KND Labs, Inc.
  • Librede, Inc.
  • Lygos, Inc.
  • Medical Marijuana, Inc.
  • Mile High Labs, LLC
  • Open Book Extracts, LLC
  • ProVerde Laboratories, Inc.
  • Renew Biopharma, Inc.
  • Scandinavian Biopharma AB
  • Teewinot Life Sciences
  • Tilray Brands, Inc.
Product Code: MRR-3A2E844FF091

The Minor Cannabinoids Market is projected to grow by USD 35.86 billion at a CAGR of 8.55% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 20.19 billion
Estimated Year [2026] USD 21.69 billion
Forecast Year [2032] USD 35.86 billion
CAGR (%) 8.55%

Minor cannabinoids, including cannabigerol, cannabinol, cannabichromene, tetrahydrocannabivarin, cannabidivarin, and emerging acidic or varin compounds, are moving from niche phytochemistry into a strategic focus area for wellness, pharmaceutical research, cosmetics, functional ingredients, and regulated cannabis product development. Unlike the dominant cannabinoids most commonly associated with commercial cannabis products, minor cannabinoids are typically present in lower natural concentrations, requiring advanced breeding, biosynthesis, precision extraction, isolation, and analytical validation to support scalable use. Scientific interest is being driven by their distinct receptor interactions, potential entourage effects, and differentiated formulation profiles, although many therapeutic claims remain under clinical investigation and require careful regulatory positioning. The industry is increasingly shaped by quality assurance, contaminant testing, pharmacokinetic research, consumer demand for targeted effects, and jurisdiction-specific compliance requirements. As stakeholders evaluate minor cannabinoid opportunities, success depends on evidence-led product development, transparent labeling, supply chain traceability, and a disciplined approach to health claims in line with applicable cannabis, food, supplement, cosmetic, and pharmaceutical regulations.

Transformative Shifts Reshaping Minor Cannabinoids

The minor cannabinoids landscape is undergoing transformative shifts as the sector moves beyond broad-spectrum cannabis extracts toward more precise, standardized, and effect-specific formulations. Advances in plant genetics are enabling cultivars with elevated concentrations of cannabinoids such as CBG and THCV, while fermentation-based and biosynthetic production methods are being explored to address the challenge of low plant abundance and batch variability. At the same time, improved chromatography, mass spectrometry, and reference-standard testing are strengthening cannabinoid identification and purity verification, which is essential for clinical research, product safety, and regulatory confidence. Consumer-facing categories are also shifting from generalized CBD-style wellness positioning to outcome-oriented formats focused on sleep support, relaxation, focus, recovery, and skin health, though substantiation requirements vary significantly by jurisdiction. Regulatory scrutiny is intensifying around intoxicating hemp-derived compounds, synthetic conversion pathways, residual solvents, labeling accuracy, and age-gated access. These shifts are pushing the industry toward pharmaceutical-grade documentation, validated manufacturing controls, and science-backed claims rather than trend-driven commercialization.

Cumulative Impact of Artificial Intelligence on Minor Cannabinoids

Artificial intelligence is increasingly influencing the minor cannabinoids value chain by accelerating compound discovery, optimizing cultivation variables, improving extraction efficiency, and supporting regulatory intelligence. In research settings, machine learning models can help analyze cannabinoid-receptor interactions, screen molecular analogs, and identify promising candidates for further laboratory and clinical evaluation. In agriculture, AI-enabled environmental monitoring supports controlled cultivation by correlating light spectrum, nutrients, humidity, and harvest timing with cannabinoid expression, helping reduce variability in specialty biomass. In manufacturing, predictive analytics can improve process control for extraction, purification, and stability testing, while computer vision and spectroscopy-assisted systems can enhance quality inspection. AI is also being applied to adverse event monitoring, literature surveillance, patent mapping, and compliance tracking across fragmented cannabis regulations. However, the cumulative impact of AI depends on data quality, validated models, privacy controls, and human oversight. Because cannabinoid science remains an evolving evidence base, AI should be used to augment experimental design and decision-making rather than replace toxicology, pharmacology, clinical validation, or regulatory review.

Key Regional Insights Across the Minor Cannabinoids Ecosystem

Asia-Pacific is emerging as a scientifically important region for cannabinoid research and regulated medical cannabis development, with Australia, Japan, South Korea, India, China, and Thailand showing varied approaches to cannabis-derived ingredients, pharmaceutical pathways, hemp cultivation, and industrial applications. Australia has established regulated medical cannabis access and research activity, while Japan and South Korea maintain stricter controls with carefully defined cannabinoid permissions and evolving interest in non-intoxicating ingredients. China has a long history of industrial hemp activity in selected provinces, particularly for fiber and seed applications, though cannabinoid use remains tightly restricted. North America remains the most commercially developed region for minor cannabinoids, supported by Canada's federal cannabis framework and the United States' complex split between state-regulated cannabis markets and federally regulated hemp parameters. This regional complexity has encouraged innovation in CBG, CBN, CBC, and THCV products while also raising enforcement concerns around intoxicating hemp derivatives and inconsistent labeling. Latin America is gaining relevance through medical cannabis reforms, hemp policy discussions, and pharmaceutical import channels, with Brazil, Mexico, Colombia, Argentina, and Chile demonstrating differing levels of patient access, cultivation permissions, and regulatory maturity. Europe is characterized by stringent novel food, pharmaceutical, narcotics, and cosmetic rules, creating high compliance expectations for cannabinoid ingredients, especially where isolated or enriched minor cannabinoids are used. The Middle East remains cautious, with select jurisdictions allowing limited medical or pharmaceutical cannabinoid access under strict controls, while broader cannabis commercialization remains heavily restricted. Africa presents long-term cultivation and export potential in countries that have introduced medical cannabis or industrial hemp frameworks, but infrastructure, certification, investment, and international compliance requirements remain decisive for participation in the minor cannabinoids supply chain.

Key Group Insights for Minor Cannabinoids Regulation and Adoption

Within ASEAN, policy approaches to minor cannabinoids remain highly diverse, ranging from Thailand's cannabis policy experimentation and subsequent regulatory tightening to more restrictive regimes in Singapore, Malaysia, Indonesia, Vietnam, and the Philippines, where narcotics laws significantly constrain commercial cannabinoid activity. This creates selective opportunities for medical, research, and hemp-linked applications but requires rigorous jurisdictional review. The GCC maintains some of the world's strictest drug control environments, and while pharmaceutical cannabinoid access may be possible through controlled medical channels in limited circumstances, commercial minor cannabinoid products face substantial legal barriers. The European Union applies a complex framework involving narcotics controls, food safety assessments, novel food authorization, cosmetics rules, and national-level medical cannabis systems, making compliance documentation, toxicology data, and ingredient traceability essential for market entry. BRICS countries collectively represent a heterogeneous landscape: Brazil and South Africa have established pathways for medical cannabis or hemp-related activity, China and India have industrial or traditional plant-use contexts with strict cannabinoid controls, and Russia maintains restrictive cannabis laws. G7 countries are especially influential in shaping quality standards, pharmacovigilance practices, analytical testing expectations, and consumer safety norms, with Canada, the United States, Germany, France, Italy, Japan, and the United Kingdom each applying distinct cannabis and hemp rules. NATO members also present a mixed regulatory profile, as North American and European members differ on medical cannabis access, hemp-derived cannabinoids, product labeling, and defense-related restrictions, but they collectively reinforce the importance of controlled supply chains, validated testing, and policy alignment with public health and security objectives.

Key Country Insights Shaping Minor Cannabinoids Strategy

The United States is one of the most active environments for minor cannabinoid innovation due to state cannabis programs, hemp-derived product development, and consumer interest in targeted cannabinoid formats, though federal uncertainty and state-by-state restrictions create compliance complexity. Canada benefits from a national cannabis framework that supports regulated product development and analytical oversight, making it important for standardized cannabinoid formats. Mexico has moved through significant legal and policy debate around cannabis, but operational clarity for broad commercial cannabinoid activity remains limited. Brazil has become a notable medical cannabis access country through health-authority pathways, with patient demand largely shaped by prescription and import mechanisms. The United Kingdom permits tightly regulated medical cannabis prescribing and has specific controls for CBD and controlled cannabinoids, making minor cannabinoid commercialization dependent on careful compliance. Germany is influential due to its medical cannabis system and evolving adult-use reforms, while France maintains a cautious approach shaped by medical trials, hemp rules, and strict consumer product oversight. Russia remains restrictive toward cannabis and cannabinoid commercialization. Italy and Spain have active hemp and medical cannabis discussions, yet both require careful navigation of national rules on THC thresholds, product claims, and narcotics controls. China's role is more aligned with industrial hemp capability and manufacturing expertise than open cannabinoid consumer markets, given strict domestic controls. India has traditional cannabis-related contexts and pharmaceutical interest, but modern cannabinoid commercialization must align with narcotics, state, and medical regulations. Japan enforces strict cannabis controls while showing growing scrutiny and selective acceptance of non-intoxicating cannabinoid ingredients under defined conditions. Australia has a structured medical cannabis framework and established patient access channels, making it a key regulated market for cannabinoid research and compliant products. South Korea allows limited medical cannabis access under controlled conditions, with strict restrictions on broader cannabinoid commercialization.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize evidence-based differentiation by investing in validated analytical testing, stability data, toxicology review, and clinical or observational research where appropriate. Product teams should avoid unsupported therapeutic claims and instead align labeling, marketing, and consumer education with the specific rules governing cannabis, hemp, supplements, foods, cosmetics, or medicines in each jurisdiction. Supply chain leaders should strengthen traceability from genetics or biosynthetic inputs through finished goods, including documentation for cannabinoid identity, residual solvents, pesticides, heavy metals, microbial contaminants, and conversion byproducts. Manufacturers should evaluate whether plant-derived extraction, enriched biomass, semi-synthetic conversion, or biosynthesis best fits the target jurisdiction's legal framework and quality requirements. Regulatory teams should maintain active monitoring of fast-changing policies around intoxicating hemp derivatives, novel foods, medical cannabis access, import-export controls, and controlled-substance scheduling. Commercial leaders should focus on targeted, transparent formulations that clearly explain cannabinoid content, serving size, onset expectations, and safety considerations. Strategic partnerships with accredited laboratories, clinical researchers, cultivators, and regulatory specialists can reduce risk and improve credibility. Above all, leaders should build compliance-first operating models capable of adapting to rapid policy change while maintaining consumer safety and scientific integrity.

Research Methodology

This executive summary is developed using a structured secondary research approach focused on verified public-domain sources, regulatory documentation, scientific literature, and industry-relevant policy materials. The methodology emphasizes cross-validation across government publications, health authority guidance, peer-reviewed research, international drug control references, standards organizations, and publicly available legal frameworks. The analysis excludes market sizing, market share, and forecasting to maintain focus on regulatory, technological, scientific, and strategic dynamics. Regional, group, and country insights are synthesized by comparing cannabis, hemp, medical access, controlled-substance, food, supplement, cosmetic, and pharmaceutical rules where applicable. Scientific interpretation is framed cautiously, distinguishing between preclinical findings, early-stage research, approved medical uses of cannabinoid-based medicines, and unverified commercial claims. Technology insights, including artificial intelligence applications, are assessed through their relevance to cultivation, extraction, analytics, pharmacology, product development, and compliance workflows. The research approach prioritizes accuracy, traceability, and practical relevance for decision-makers navigating the evolving minor cannabinoids ecosystem.

Conclusion

Minor cannabinoids are becoming a high-interest segment of the broader cannabis and hemp ecosystem because they offer differentiated formulation potential, expanding research relevance, and new opportunities for precision product development. The path to sustainable growth, however, is defined less by novelty and more by evidence, compliance, safety, and manufacturing consistency. Regulatory divergence across regions and countries remains one of the most important strategic challenges, particularly for isolated, enriched, biosynthetic, or chemically converted cannabinoids. Artificial intelligence, advanced analytics, controlled cultivation, and improved purification technologies are strengthening the industry's ability to identify, standardize, and validate minor cannabinoid ingredients, but scientific substantiation and responsible commercialization remain essential. Organizations that combine rigorous testing, transparent labeling, adaptable regulatory strategy, and credible research partnerships will be best positioned to build trust in minor cannabinoids across medical, wellness, cosmetic, and specialty consumer applications.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Minor Cannabinoids Market, by Product Type

  • 7.1. Introduction
  • 7.2. Cannabichromene
  • 7.3. Cannabigerol
  • 7.4. Cannabinol
  • 7.5. Delta-8-Thc
  • 7.6. THCV

8. Minor Cannabinoids Market, by Form

  • 8.1. Introduction
  • 8.2. Beverages
    • 8.2.1. Energy Drinks
    • 8.2.2. Infused Water
    • 8.2.3. Teas
  • 8.3. Capsules
  • 8.4. Edibles
    • 8.4.1. Baked Goods
    • 8.4.2. Chocolates
    • 8.4.3. Gummies
  • 8.5. Oil
  • 8.6. Tinctures
  • 8.7. Topicals

9. Minor Cannabinoids Market, by Application

  • 9.1. Introduction
  • 9.2. Medical & Therapeutic Uses
    • 9.2.1. Pain & Inflammation Management
    • 9.2.2. Sleep & Circadian Disorders
    • 9.2.3. Anxiety, Stress & Mood Disorders
    • 9.2.4. Neurological & Neuroprotective Uses
    • 9.2.5. Metabolic & Appetite Regulation
  • 9.3. Wellness & Lifestyle Uses
    • 9.3.1. Everyday Relaxation & Stress Relief
    • 9.3.2. Focus, Energy & Productivity
    • 9.3.3. Fitness & Sports Recovery
    • 9.3.4. Healthy Aging & Longevity
  • 9.4. Cosmetic & Personal Care Uses
    • 9.4.1. Skin Care
    • 9.4.2. Hair & Scalp Care
    • 9.4.3. Oral & Dental Care
  • 9.5. Veterinary Uses
    • 9.5.1. Companion Animals
    • 9.5.2. Performance & Working Animals

10. Minor Cannabinoids Market, by Sales Channel

  • 10.1. Introduction
  • 10.2. Online Channels
  • 10.3. Offline Channels

11. Minor Cannabinoids Market, by Region

  • 11.1. Asia-Pacific
  • 11.2. North America
  • 11.3. Latin America
  • 11.4. Europe
  • 11.5. Middle East
  • 11.6. Africa

12. Minor Cannabinoids Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Minor Cannabinoids Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2025
  • 14.2. FPNV Positioning Matrix, 2025
  • 14.3. Market Concentration Analysis, 2025
    • 14.3.1. Concentration Ratio (CR)
    • 14.3.2. Herfindahl Hirschman Index (HHI)
  • 14.4. Recent Developments & Impact Analysis, 2025
  • 14.5. Product Portfolio Analysis, 2025
  • 14.6. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. Amyris, Inc.
  • 15.2. Aurora Cannabis Inc.
  • 15.3. BayMedica
  • 15.4. Biomedican Inc.
  • 15.5. Bluebird Botanicals, LLC
  • 15.6. Botanacor Laboratories, Inc.
  • 15.7. Canopy Growth Corporation
  • 15.8. Cronos Group, Inc.
  • 15.9. CV Sciences, Inc.
  • 15.10. Demetrix, Inc.
  • 15.11. ExtraktLAB, Inc.
  • 15.12. Folium Biosciences, Inc.
  • 15.13. Ginkgo Bioworks, Inc.
  • 15.14. Green Thumb Industries Inc
  • 15.15. GW Pharmaceuticals Limited
  • 15.16. Hyasynth Bio, Inc.
  • 15.17. Isodiol International Inc.
  • 15.18. KND Labs, Inc.
  • 15.19. Librede, Inc.
  • 15.20. Lygos, Inc.
  • 15.21. Medical Marijuana, Inc.
  • 15.22. Mile High Labs, LLC
  • 15.23. Open Book Extracts, LLC
  • 15.24. ProVerde Laboratories, Inc.
  • 15.25. Renew Biopharma, Inc.
  • 15.26. Scandinavian Biopharma AB
  • 15.27. Teewinot Life Sciences
  • 15.28. Tilray Brands, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MINOR CANNABINOIDS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL MINOR CANNABINOIDS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL MINOR CANNABINOIDS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL MINOR CANNABINOIDS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL MINOR CANNABINOIDS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY FORM, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY SALES CHANNEL, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY SALES CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL MINOR CANNABINOIDS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 21. GLOBAL MINOR CANNABINOIDS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL MINOR CANNABINOIDS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL MINOR CANNABINOIDS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CANNABICHROMENE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CANNABICHROMENE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CANNABICHROMENE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CANNABIGEROL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CANNABIGEROL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CANNABIGEROL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CANNABINOL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CANNABINOL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CANNABINOL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DELTA-8-THC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DELTA-8-THC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DELTA-8-THC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL THCV MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL THCV MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL THCV MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BEVERAGES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BEVERAGES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BEVERAGES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ENERGY DRINKS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ENERGY DRINKS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ENERGY DRINKS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL INFUSED WATER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL INFUSED WATER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL INFUSED WATER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL TEAS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TEAS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TEAS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CAPSULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CAPSULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL EDIBLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL EDIBLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL EDIBLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BAKED GOODS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BAKED GOODS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BAKED GOODS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CHOCOLATES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CHOCOLATES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CHOCOLATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GUMMIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GUMMIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GUMMIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL OIL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL OIL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL OIL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL TINCTURES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL TINCTURES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL TINCTURES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL TOPICALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL TOPICALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL TOPICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MEDICAL & THERAPEUTIC USES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MEDICAL & THERAPEUTIC USES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL MEDICAL & THERAPEUTIC USES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PAIN & INFLAMMATION MANAGEMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PAIN & INFLAMMATION MANAGEMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PAIN & INFLAMMATION MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL SLEEP & CIRCADIAN DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL SLEEP & CIRCADIAN DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL SLEEP & CIRCADIAN DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANXIETY, STRESS & MOOD DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANXIETY, STRESS & MOOD DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ANXIETY, STRESS & MOOD DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEUROLOGICAL & NEUROPROTECTIVE USES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NEUROLOGICAL & NEUROPROTECTIVE USES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEUROLOGICAL & NEUROPROTECTIVE USES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL METABOLIC & APPETITE REGULATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL METABOLIC & APPETITE REGULATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL METABOLIC & APPETITE REGULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL WELLNESS & LIFESTYLE USES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL WELLNESS & LIFESTYLE USES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL WELLNESS & LIFESTYLE USES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL EVERYDAY RELAXATION & STRESS RELIEF MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL EVERYDAY RELAXATION & STRESS RELIEF MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL EVERYDAY RELAXATION & STRESS RELIEF MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL FOCUS, ENERGY & PRODUCTIVITY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL FOCUS, ENERGY & PRODUCTIVITY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL FOCUS, ENERGY & PRODUCTIVITY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL FITNESS & SPORTS RECOVERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL FITNESS & SPORTS RECOVERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL FITNESS & SPORTS RECOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL HEALTHY AGING & LONGEVITY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL HEALTHY AGING & LONGEVITY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL HEALTHY AGING & LONGEVITY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL COSMETIC & PERSONAL CARE USES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL COSMETIC & PERSONAL CARE USES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL COSMETIC & PERSONAL CARE USES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL SKIN CARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL SKIN CARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL SKIN CARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL HAIR & SCALP CARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL HAIR & SCALP CARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL HAIR & SCALP CARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ORAL & DENTAL CARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ORAL & DENTAL CARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ORAL & DENTAL CARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL VETERINARY USES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL VETERINARY USES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL VETERINARY USES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL COMPANION ANIMALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL COMPANION ANIMALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL COMPANION ANIMALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL PERFORMANCE & WORKING ANIMALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL PERFORMANCE & WORKING ANIMALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL PERFORMANCE & WORKING ANIMALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ONLINE CHANNELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ONLINE CHANNELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ONLINE CHANNELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL OFFLINE CHANNELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL OFFLINE CHANNELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL OFFLINE CHANNELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC MINOR CANNABINOIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC MINOR CANNABINOIDS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC MINOR CANNABINOIDS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC MINOR CANNABINOIDS MARKET SIZE, BY BEVERAGES, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC MINOR CANNABINOIDS MARKET SIZE, BY EDIBLES, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC MINOR CANNABINOIDS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC MINOR CANNABINOIDS MARKET SIZE, BY MEDICAL & THERAPEUTIC USES, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC MINOR CANNABINOIDS MARKET SIZE, BY WELLNESS & LIFESTYLE USES, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC MINOR CANNABINOIDS MARKET SIZE, BY COSMETIC & PERSONAL CARE USES, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC MINOR CANNABINOIDS MARKET SIZE, BY VETERINARY USES, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC MINOR CANNABINOIDS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA MINOR CANNABINOIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA MINOR CANNABINOIDS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA MINOR CANNABINOIDS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA MINOR CANNABINOIDS MARKET SIZE, BY BEVERAGES, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA MINOR CANNABINOIDS MARKET SIZE, BY EDIBLES, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA MINOR CANNABINOIDS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA MINOR CANNABINOIDS MARKET SIZE, BY MEDICAL & THERAPEUTIC USES, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA MINOR CANNABINOIDS MARKET SIZE, BY WELLNESS & LIFESTYLE USES, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA MINOR CANNABINOIDS MARKET SIZE, BY COSMETIC & PERSONAL CARE USES, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA MINOR CANNABINOIDS MARKET SIZE, BY VETERINARY USES, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA MINOR CANNABINOIDS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA MINOR CANNABINOIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA MINOR CANNABINOIDS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA MINOR CANNABINOIDS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA MINOR CANNABINOIDS MARKET SIZE, BY BEVERAGES, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA MINOR CANNABINOIDS MARKET SIZE, BY EDIBLES, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA MINOR CANNABINOIDS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA MINOR CANNABINOIDS MARKET SIZE, BY MEDICAL & THERAPEUTIC USES, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA MINOR CANNABINOIDS MARKET SIZE, BY WELLNESS & LIFESTYLE USES, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA MINOR CANNABINOIDS MARKET SIZE, BY COSMETIC & PERSONAL CARE USES, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA MINOR CANNABINOIDS MARKET SIZE, BY VETERINARY USES, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA MINOR CANNABINOIDS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE MINOR CANNABINOIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE MINOR CANNABINOIDS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE MINOR CANNABINOIDS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE MINOR CANNABINOIDS MARKET SIZE, BY BEVERAGES, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE MINOR CANNABINOIDS MARKET SIZE, BY EDIBLES, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE MINOR CANNABINOIDS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE MINOR CANNABINOIDS MARKET SIZE, BY MEDICAL & THERAPEUTIC USES, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE MINOR CANNABINOIDS MARKET SIZE, BY WELLNESS & LIFESTYLE USES, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE MINOR CANNABINOIDS MARKET SIZE, BY COSMETIC & PERSONAL CARE USES, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE MINOR CANNABINOIDS MARKET SIZE, BY VETERINARY USES, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE MINOR CANNABINOIDS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST MINOR CANNABINOIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST MINOR CANNABINOIDS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST MINOR CANNABINOIDS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST MINOR CANNABINOIDS MARKET SIZE, BY BEVERAGES, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST MINOR CANNABINOIDS MARKET SIZE, BY EDIBLES, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST MINOR CANNABINOIDS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST MINOR CANNABINOIDS MARKET SIZE, BY MEDICAL & THERAPEUTIC USES, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST MINOR CANNABINOIDS MARKET SIZE, BY WELLNESS & LIFESTYLE USES, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST MINOR CANNABINOIDS MARKET SIZE, BY COSMETIC & PERSONAL CARE USES, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST MINOR CANNABINOIDS MARKET SIZE, BY VETERINARY USES, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST MINOR CANNABINOIDS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA MINOR CANNABINOIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA MINOR CANNABINOIDS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA MINOR CANNABINOIDS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA MINOR CANNABINOIDS MARKET SIZE, BY BEVERAGES, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA MINOR CANNABINOIDS MARKET SIZE, BY EDIBLES, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA MINOR CANNABINOIDS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA MINOR CANNABINOIDS MARKET SIZE, BY MEDICAL & THERAPEUTIC USES, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA MINOR CANNABINOIDS MARKET SIZE, BY WELLNESS & LIFESTYLE USES, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA MINOR CANNABINOIDS MARKET SIZE, BY COSMETIC & PERSONAL CARE USES, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA MINOR CANNABINOIDS MARKET SIZE, BY VETERINARY USES, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA MINOR CANNABINOIDS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN MINOR CANNABINOIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN MINOR CANNABINOIDS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN MINOR CANNABINOIDS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN MINOR CANNABINOIDS MARKET SIZE, BY BEVERAGES, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN MINOR CANNABINOIDS MARKET SIZE, BY EDIBLES, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN MINOR CANNABINOIDS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN MINOR CANNABINOIDS MARKET SIZE, BY MEDICAL & THERAPEUTIC USES, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN MINOR CANNABINOIDS MARKET SIZE, BY WELLNESS & LIFESTYLE USES, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN MINOR CANNABINOIDS MARKET SIZE, BY COSMETIC & PERSONAL CARE USES, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN MINOR CANNABINOIDS MARKET SIZE, BY VETERINARY USES, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN MINOR CANNABINOIDS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. GCC MINOR CANNABINOIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 198. GCC MINOR CANNABINOIDS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. GCC MINOR CANNABINOIDS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 200. GCC MINOR CANNABINOIDS MARKET SIZE, BY BEVERAGES, 2018-2032 (USD MILLION)
  • TABLE 201. GCC MINOR CANNABINOIDS MARKET SIZE, BY EDIBLES, 2018-2032 (USD MILLION)
  • TABLE 202. GCC MINOR CANNABINOIDS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 203. GCC MINOR CANNABINOIDS MARKET SIZE, BY MEDICAL & THERAPEUTIC USES, 2018-2032 (USD MILLION)
  • TABLE 204. GCC MINOR CANNABINOIDS MARKET SIZE, BY WELLNESS & LIFESTYLE USES, 2018-2032 (USD MILLION)
  • TABLE 205. GCC MINOR CANNABINOIDS MARKET SIZE, BY COSMETIC & PERSONAL CARE USES, 2018-2032 (USD MILLION)
  • TABLE 206. GCC MINOR CANNABINOIDS MARKET SIZE, BY VETERINARY USES, 2018-2032 (USD MILLION)
  • TABLE 207. GCC MINOR CANNABINOIDS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION MINOR CANNABINOIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION MINOR CANNABINOIDS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION MINOR CANNABINOIDS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION MINOR CANNABINOIDS MARKET SIZE, BY BEVERAGES, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION MINOR CANNABINOIDS MARKET SIZE, BY EDIBLES, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION MINOR CANNABINOIDS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION MINOR CANNABINOIDS MARKET SIZE, BY MEDICAL & THERAPEUTIC USES, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION MINOR CANNABINOIDS MARKET SIZE, BY WELLNESS & LIFESTYLE USES, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION MINOR CANNABINOIDS MARKET SIZE, BY COSMETIC & PERSONAL CARE USES, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION MINOR CANNABINOIDS MARKET SIZE, BY VETERINARY USES, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION MINOR CANNABINOIDS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS MINOR CANNABINOIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS MINOR CANNABINOIDS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS MINOR CANNABINOIDS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS MINOR CANNABINOIDS MARKET SIZE, BY BEVERAGES, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS MINOR CANNABINOIDS MARKET SIZE, BY EDIBLES, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS MINOR CANNABINOIDS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS MINOR CANNABINOIDS MARKET SIZE, BY MEDICAL & THERAPEUTIC USES, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS MINOR CANNABINOIDS MARKET SIZE, BY WELLNESS & LIFESTYLE USES, 2018-2032 (USD MILLION)
  • TABLE 227. BRICS MINOR CANNABINOIDS MARKET SIZE, BY COSMETIC & PERSONAL CARE USES, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS MINOR CANNABINOIDS MARKET SIZE, BY VETERINARY USES, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS MINOR CANNABINOIDS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 230. G7 MINOR CANNABINOIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 231. G7 MINOR CANNABINOIDS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. G7 MINOR CANNABINOIDS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 233. G7 MINOR CANNABINOIDS MARKET SIZE, BY BEVERAGES, 2018-2032 (USD MILLION)
  • TABLE 234. G7 MINOR CANNABINOIDS MARKET SIZE, BY EDIBLES, 2018-2032 (USD MILLION)
  • TABLE 235. G7 MINOR CANNABINOIDS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 236. G7 MINOR CANNABINOIDS MARKET SIZE, BY MEDICAL & THERAPEUTIC USES, 2018-2032 (USD MILLION)
  • TABLE 237. G7 MINOR CANNABINOIDS MARKET SIZE, BY WELLNESS & LIFESTYLE USES, 2018-2032 (USD MILLION)
  • TABLE 238. G7 MINOR CANNABINOIDS MARKET SIZE, BY COSMETIC & PERSONAL CARE USES, 2018-2032 (USD MILLION)
  • TABLE 239. G7 MINOR CANNABINOIDS MARKET SIZE, BY VETERINARY USES, 2018-2032 (USD MILLION)
  • TABLE 240. G7 MINOR CANNABINOIDS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 241. NATO MINOR CANNABINOIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 242. NATO MINOR CANNABINOIDS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. NATO MINOR CANNABINOIDS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 244. NATO MINOR CANNABINOIDS MARKET SIZE, BY BEVERAGES, 2018-2032 (USD MILLION)
  • TABLE 245. NATO MINOR CANNABINOIDS MARKET SIZE, BY EDIBLES, 2018-2032 (USD MILLION)
  • TABLE 246. NATO MINOR CANNABINOIDS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 247. NATO MINOR CANNABINOIDS MARKET SIZE, BY MEDICAL & THERAPEUTIC USES, 2018-2032 (USD MILLION)
  • TABLE 248. NATO MINOR CANNABINOIDS MARKET SIZE, BY WELLNESS & LIFESTYLE USES, 2018-2032 (USD MILLION)
  • TABLE 249. NATO MINOR CANNABINOIDS MARKET SIZE, BY COSMETIC & PERSONAL CARE USES, 2018-2032 (USD MILLION)
  • TABLE 250. NATO MINOR CANNABINOIDS MARKET SIZE, BY VETERINARY USES, 2018-2032 (USD MILLION)
  • TABLE 251. NATO MINOR CANNABINOIDS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 252. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES MINOR CANNABINOIDS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES MINOR CANNABINOIDS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED STATES MINOR CANNABINOIDS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES MINOR CANNABINOIDS MARKET SIZE, BY BEVERAGES, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES MINOR CANNABINOIDS MARKET SIZE, BY EDIBLES, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED STATES MINOR CANNABINOIDS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES MINOR CANNABINOIDS MARKET SIZE, BY MEDICAL & THERAPEUTIC USES, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES MINOR CANNABINOIDS MARKET SIZE, BY WELLNESS & LIFESTYLE USES, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED STATES MINOR CANNABINOIDS MARKET SIZE, BY COSMETIC & PERSONAL CARE USES, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES MINOR CANNABINOIDS MARKET SIZE, BY VETERINARY USES, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED STATES MINOR CANNABINOIDS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 264. CANADA MINOR CANNABINOIDS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 265. CANADA MINOR CANNABINOIDS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. CANADA MINOR CANNABINOIDS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 267. CANADA MINOR CANNABINOIDS MARKET SIZE, BY BEVERAGES, 2018-2032 (USD MILLION)
  • TABLE 268. CANADA MINOR CANNABINOIDS MARKET SIZE, BY EDIBLES, 2018-2032 (USD MILLION)
  • TABLE 269. CANADA MINOR CANNABINOIDS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 270. CANADA MINOR CANNABINOIDS MARKET SIZE, BY MEDICAL & THERAPEUTIC USES, 2018-2032 (USD MILLION)
  • TABLE 271. CANADA MINOR CANNABINOIDS MARKET SIZE, BY WELLNESS & LIFESTYLE USES, 2018-2032 (USD MILLION)
  • TABLE 272. CANADA MINOR CANNABINOIDS MARKET SIZE, BY COSMETIC & PERSONAL CARE USES, 2018-2032 (USD MILLION)
  • TABLE 273. CANADA MINOR CANNABINOIDS MARKET SIZE, BY VETERINARY USES, 2018-2032 (USD MILLION)
  • TABLE 274. CANADA MINOR CANNABINOIDS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 275. MEXICO MINOR CANNABINOIDS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 276. MEXICO MINOR CANNABINOIDS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 277. MEXICO MINOR CANNABINOIDS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 278. MEXICO MINOR CANNABINOIDS MARKET SIZE, BY BEVERAGES, 2018-2032 (USD MILLION)
  • TABLE 279. MEXICO MINOR CANNABINOIDS MARKET SIZE, BY EDIBLES, 2018-2032 (USD MILLION)
  • TABLE 280. MEXICO MINOR CANNABINOIDS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 281. MEXICO MINOR CANNABINOIDS MARKET SIZE, BY MEDICAL & THERAPEUTIC USES, 2018-2032 (USD MILLION)
  • TABLE 282. MEXICO MINOR CANNABINOIDS MARKET SIZE, BY WELLNESS & LIFESTYLE USES, 2018-2032 (USD MILLION)
  • TABLE 283. MEXICO MINOR CANNABINOIDS MARKET SIZE, BY COSMETIC & PERSONAL CARE USES, 2018-2032 (USD MILLION)
  • TABLE 284. MEXICO MINOR CANNABINOIDS MARKET SIZE, BY VETERINARY USES, 2018-2032 (USD MILLION)
  • TABLE 285. MEXICO MINOR CANNABINOIDS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 286. BRAZIL MINOR CANNABINOIDS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 287. BRAZIL MINOR CANNABINOIDS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. BRAZIL MINOR CANNABINOIDS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 289. BRAZIL MINOR CANNABINOIDS MARKET SIZE, BY BEVERAGES, 2018-2032 (USD MILLION)
  • TABLE 290. BRAZIL MINOR CANNABINOIDS MARKET SIZE, BY EDIBLES, 2018-2032 (USD MILLION)
  • TABLE 291. BRAZIL MINOR CANNABINOIDS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 292. BRAZIL MINOR CANNABINOIDS MARKET SIZE, BY MEDICAL & THERAPEUTIC USES, 2018-2032 (USD MILLION)
  • TABLE 293. BRAZIL MINOR CANNABINOIDS MARKET SIZE, BY WELLNESS & LIFESTYLE USES, 2018-2032 (USD MILLION)
  • TABLE 294. BRAZIL MINOR CANNABINOIDS MARKET SIZE, BY COSMETIC & PERSONAL CARE USES, 2018-2032 (USD MILLION)
  • TABLE 295. BRAZIL MINOR CANNABINOIDS MARKET SIZE, BY VETERINARY USES, 2018-2032 (USD MILLION)
  • TABLE 296. BRAZIL MINOR CANNABINOIDS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED KINGDOM MINOR CANNABINOIDS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 298. UNITED KINGDOM MINOR CANNABINOIDS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 299. UNITED KINGDOM MINOR CANNABINOIDS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 300. UNITED KINGDOM MINOR CANNABINOIDS MARKET SIZE, BY BEVERAGES, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED KINGDOM MINOR CANNABINOIDS MARKET SIZE, BY EDIBLES, 2018-2032 (USD MILLION)
  • TABLE 302. UNITED KINGDOM MINOR CANNABINOIDS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 303. UNITED KINGDOM MINOR CANNABINOIDS MARKET SIZE, BY MEDICAL & THERAPEUTIC USES, 2018-2032 (USD MILLION)
  • TABLE 304. UNITED KINGDOM MINOR CANNABINOIDS MARKET SIZE, BY WELLNESS & LIFESTYLE USES, 2018-2032 (USD MILLION)
  • TABLE 305. UNITED KINGDOM MINOR CANNABINOIDS MARKET SIZE, BY COSMETIC & PERSONAL CARE USES, 2018-2032 (USD MILLION)
  • TABLE 306. UNITED KINGDOM MINOR CANNABINOIDS MARKET SIZE, BY VETERINARY USES, 2018-2032 (USD MILLION)
  • TABLE 307. UNITED KINGDOM MINOR CANNABINOIDS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 308. GERMANY MINOR CANNABINOIDS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 309. GERMANY MINOR CANNABINOIDS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 310. GERMANY MINOR CANNABINOIDS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 311. GERMANY MINOR CANNABINOIDS MARKET SIZE, BY BEVERAGES, 2018-2032 (USD MILLION)
  • TABLE 312. GERMANY MINOR CANNABINOIDS MARKET SIZE, BY EDIBLES, 2018-2032 (USD MILLION)
  • TABLE 313. GERMANY MINOR CANNABINOIDS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 314. GERMANY MINOR CANNABINOIDS MARKET SIZE, BY MEDICAL & THERAPEUTIC USES, 2018-2032 (USD MILLION)
  • TABLE 315. GERMANY MINOR CANNABINOIDS MARKET SIZE, BY WELLNESS & LIFESTYLE USES, 2018-2032 (USD MILLION)
  • TABLE 316. GERMANY MINOR CANNABINOIDS MARKET SIZE, BY COSMETIC & PERSONAL CARE USES, 2018-2032 (USD MILLION)
  • TABLE 317. GERMANY MINOR CANNABINOIDS MARKET SIZE, BY VETERINARY USES, 2018-2032 (USD MILLION)
  • TABLE 318. GERMANY MINOR CANNABINOIDS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 319. FRANCE MINOR CANNABINOIDS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 320. FRANCE MINOR CANNABINOIDS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 321. FRANCE MINOR CANNABINOIDS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 322. FRANCE MINOR CANNABINOIDS MARKET SIZE, BY BEVERAGES, 2018-2032 (USD MILLION)
  • TABLE 323. FRANCE MINOR CANNABINOIDS MARKET SIZE, BY EDIBLES, 2018-2032 (USD MILLION)
  • TABLE 324. FRANCE MINOR CANNABINOIDS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 325. FRANCE MINOR CANNABINOIDS MARKET SIZE, BY MEDICAL & THERAPEUTIC USES, 2018-2032 (USD MILLION)
  • TABLE 326. FRANCE MINOR CANNABINOIDS MARKET SIZE, BY WELLNESS & LIFESTYLE USES, 2018-2032 (USD MILLION)
  • TABLE 327. FRANCE MINOR CANNABINOIDS MARKET SIZE, BY COSMETIC & PERSONAL CARE USES, 2018-2032 (USD MILLION)
  • TABLE 328. FRANCE MINOR CANNABINOIDS MARKET SIZE, BY VETERINARY USES, 2018-2032 (USD MILLION)
  • TABLE 329. FRANCE MINOR CANNABINOIDS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 330. RUSSIA MINOR CANNABINOIDS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 331. RUSSIA MINOR CANNABINOIDS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 332. RUSSIA MINOR CANNABINOIDS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 333. RUSSIA MINOR CANNABINOIDS MARKET SIZE, BY BEVERAGES, 2018-2032 (USD MILLION)
  • TABLE 334. RUSSIA MINOR CANNABINOIDS MARKET SIZE, BY EDIBLES, 2018-2032 (USD MILLION)
  • TABLE 335. RUSSIA MINOR CANNABINOIDS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 336. RUSSIA MINOR CANNABINOIDS MARKET SIZE, BY MEDICAL & THERAPEUTIC USES, 2018-2032 (USD MILLION)
  • TABLE 337. RUSSIA MINOR CANNABINOIDS MARKET SIZE, BY WELLNESS & LIFESTYLE USES, 2018-2032 (USD MILLION)
  • TABLE 338. RUSSIA MINOR CANNABINOIDS MARKET SIZE, BY COSMETIC & PERSONAL CARE USES, 2018-2032 (USD MILLION)
  • TABLE 339. RUSSIA MINOR CANNABINOIDS MARKET SIZE, BY VETERINARY USES, 2018-2032 (USD MILLION)
  • TABLE 340. RUSSIA MINOR CANNABINOIDS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 341. ITALY MINOR CANNABINOIDS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 342. ITALY MINOR CANNABINOIDS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 343. ITALY MINOR CANNABINOIDS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 344. ITALY MINOR CANNABINOIDS MARKET SIZE, BY BEVERAGES, 2018-2032 (USD MILLION)
  • TABLE 345. ITALY MINOR CANNABINOIDS MARKET SIZE, BY EDIBLES, 2018-2032 (USD MILLION)
  • TABLE 346. ITALY MINOR CANNABINOIDS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 347. ITALY MINOR CANNABINOIDS MARKET SIZE, BY MEDICAL & THERAPEUTIC USES, 2018-2032 (USD MILLION)
  • TABLE 348. ITALY MINOR CANNABINOIDS MARKET SIZE, BY WELLNESS & LIFESTYLE USES, 2018-2032 (USD MILLION)
  • TABLE 349. ITALY MINOR CANNABINOIDS MARKET SIZE, BY COSMETIC & PERSONAL CARE USES, 2018-2032 (USD MILLION)
  • TABLE 350. ITALY MINOR CANNABINOIDS MARKET SIZE, BY VETERINARY USES, 2018-2032 (USD MILLION)
  • TABLE 351. ITALY MINOR CANNABINOIDS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 352. SPAIN MINOR CANNABINOIDS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 353. SPAIN MINOR CANNABINOIDS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 354. SPAIN MINOR CANNABINOIDS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 355. SPAIN MINOR CANNABINOIDS MARKET SIZE, BY BEVERAGES, 2018-2032 (USD MILLION)
  • TABLE 356. SPAIN MINOR CANNABINOIDS MARKET SIZE, BY EDIBLES, 2018-2032 (USD MILLION)
  • TABLE 357. SPAIN MINOR CANNABINOIDS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 358. SPAIN MINOR CANNABINOIDS MARKET SIZE, BY MEDICAL & THERAPEUTIC USES, 2018-2032 (USD MILLION)
  • TABLE 359. SPAIN MINOR CANNABINOIDS MARKET SIZE, BY WELLNESS & LIFESTYLE USES, 2018-2032 (USD MILLION)
  • TABLE 360. SPAIN MINOR CANNABINOIDS MARKET SIZE, BY COSMETIC & PERSONAL CARE USES, 2018-2032 (USD MILLION)
  • TABLE 361. SPAIN MINOR CANNABINOIDS MARKET SIZE, BY VETERINARY USES, 2018-2032 (USD MILLION)

TABLE 36